VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese

International Journal of Medical Sciences

Volumn 5, Issue 2, 2008, Pages 80-86

  Yamamori, Motohiro ^a   Taniguchi, Mayuko ^b   Maeda, Shingo ^b   Nakamura, Tsutomu ^a,b   Okamura, Noboru ^b   Kuwahara, Akiko ^a   Iwaki, Koichi ^a   Tamura, Takao ^b   Aoyama, Nobuo ^a   Markova, Svetlana ^b   Kasuga, Masato ^b   Okumura, Katsuhiko ^a,b   Sakaeda, Toshiyuki ^b,c  

^a KOBE UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Colorectal adenocarcinoma; Differentiation; Genetic polymorphism; Predictive marker; Vascular endothelial growth factor

Indexed keywords

ALKALINE PHOSPHATASE; MULTIDRUG RESISTANCE PROTEIN 1; SMALL INTERFERING RNA; VASCULOTROPIN; ABCB1 PROTEIN, HUMAN; BUTYRIC ACID DERIVATIVE; GLYCOPROTEIN P; MESSENGER RNA; VASCULOTROPIN A;

ADULT; AGED; ALLELE; ARTICLE; CARCINOMA CELL; CELL LINE; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; JAPANESE; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; ADENOCARCINOMA; ASIAN; CELL TRANSFORMATION; COLORECTAL TUMOR; DRUG EFFECT; GENETICS; JAPAN; METABOLISM; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL LINE;

ADENOCARCINOMA; ADULT; AGED; ALKALINE PHOSPHATASE; ASIAN CONTINENTAL ANCESTRY GROUP; BUTYRATES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 44449170052     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.5.80     Document Type: Article

References (48)

1. Ismail T, Hallissey MT, Fielding JW. Pathologic prognostic factors for gastrointestinal cancer. World J Surg. 1995; 19: 178-83.
2. Sugao Y, Yao T, Kubo C, et al. Improved prognosis of solid-type poorly differentiated colorectal adenocarcinoma: a clinicopathological and immunohistochemical study. Histopathology. 1997; 31: 123-33.
3. Takeuchi K, Kuwano H, Tsuzuki Y, et al. Clinicopathological characteristics of poorly differentiated adenocarcinoma of the colon and rectum. Hepatogastroenterology. 2004; 51: 1698-702.
4. Van Belzen N, Dinjens WN, Eussen BH, et al. Expression of differentiation-related genes in colorectal cancer: possible implications for prognosis. Histol Histopathol. 1998; 13: 1233-42.
5. Yamamori M, Sakaeda T, Nakamura T, et al. Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem Biophys Res Commun. 2004; 325: 144-50.
6. Koyama T, Nakamura T, Komoto C, et al. MDR1 T-129C polymorphism can be predictive of differentiation, and thereby prognosis of colorectal adenocarcinomas in Japanese. Biol Pharm Bull. 2006; 29: 1449-53.
7. Komoto C, Nakamura T, Sakaeda T, et al. MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet. 2006; 21: 126-32.
8. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411: 494-8.
9. Harborth J, Elbashir SM, Bechert K, et al. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci. 2001; 114: 4557-65.
10. Nieth C, Priebsch A, Stege A, et al. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett. 2003; 545: 144-50.
11. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983; 219: 83-5.
12. Criscuolo GR, Merrill MJ, Oldfield EH. Further characterization of malignant glioma-derived vascular permeability factor. J Neurosurg. 1988; 69: 54-62.
13. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989; 161: 851-8.
14. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989; 84: 1470-8.
15. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989; 246: 1306-9.
16. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989; 246: 1309-12.
17. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenes. Am J Physiol Cell Physiol. 2001; 280: 1358-66.
18. Bates DO, Harper SJ. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol. 2002; 39: 225-37.
19. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 2004; 9(Suppl. 1): 2-10.
20. Nakasaki T, Wada H, Shigemori C, et al. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol. 2002; 69: 247-54.
21. Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer. 1998; 78: 1379-84.
22. Wong MP, Cheung N, Yuen ST, et al. Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression. Int J Cancer. 1999; 81: 845-50.
23. Harada Y, Ogata Y, Shirouzu K. Expression of vascular endothelial growth factor and its receptor KDR (kinase domain-containing receptor)/Flk-1 (fetal liver kinase-1) as prognostic factors in human colorectal cancer. Int J Clin Oncol. 2001; 6: 221-8.
24. Kawakami M, Furuhata T, Kimura Y, et al. Expression analysis of vascular endothelial growth factors and their relationships to lymph node metastasis in human colorectal cancer. J Exp Clin Cancer Res. 2003; 22: 229-37.
25. Tsuji T, Sasaki Y, Tanaka M, et al. Microvessel morphology and vascular endothelial growth factor expression in human colonic carcinoma with or without metastasis. Lab Invest. 2002; 82: 555-62.
26. Zheng S, Han MY, Xiao ZX, et al. Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma. World J Gastroenterol. 2003; 9: 1227-30.
27. Watson CJ, Webb NJ, Bottomley MJ, et al. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000; 12: 1232-5.
28. Shahbazi M, Fryer AA, Pravica V, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol. 2002; 13: 260-4.
29. Renner W, Kotschan S, Hoffmann C, et al. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J. Vasc Res. 2000; 37: 443-8.
30. Krippl P, Langsenlehner U, Renner W, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer. 2003; 106: 468-71.
31. McCarron SL, Edwards S, Evans PR, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 2002; 62: 3369-72.
32. Howell WM, Bateman AC, Turner SJ, et al. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun. 2002; 3: 229-32.
33. Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002; 51: 1635-9.
34. Potocnik U, Ravnik-Glavac M, Golouh R, et al. Naturally occurring mutations and functional polymorphisms in multidrug resistance 1 gene: correlation with microsatellite instability and lymphoid infiltration in colorectal cancers. J Med Genet. 2002; 39: 340-6.
35. Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull. 2002; 25: 1391-400.
36. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics. 2003; 4: 397-410.
37. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr Top Med Chem. 2004; 4: 1385-98.
38. Okamura N, Sakaeda T, Okumura K. Pharmacogenomics of MDR and MRP subfamilies. Personalized Med. 2004; 1: 85-104.
39. Sakaeda T. MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet. 2005; 20: 391-414.
40. Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Design. 2006; 12: 273-86.
41. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 1991; 66: 85-94.
42. Sakaeda T, Nakamura T, Hirai M, et al. MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling. Pharm Res. 2002; 19: 1323-9.
43. Goto M, Masuda S, Saito H, et al. Decreased expression of P-glycoprotein during differentiation in the human intestinal cell line Caco-2. Biochem Pharmacol. 2003; 66: 163-70.
44. Oudard S, Levalois C, Andrieu JM, et al. Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res. 2002; 22: 121-8.
45. Hiroshita E, Takeshi U, Kenichi T, et al. Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res. 2000; 6: 2401-7.
46. Arnal M, Franco N, Fargeot P, et al. Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer. Breast Cancer Res Treat. 2000; 61: 13-20.
47. Purdie CA, Piris J. Histopathological grade, mucinous differentiation and DNA ploidy in relation to prognosis in colorectal carcinoma. Histopathology. 2000; 36: 121-6.
48. Chung CK, Zaino R J, Stryker JA. Colorectal carcinoma: evaluation of histologic grade and factors influencing prognosis. J Surg Oncol. 1982; 21: 143-8.